Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PID Clear all
Active, not recruiting Phase 3 Interventional

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

NCT06076642
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Effect of Gain on Closed-Loop Insulin

NCT02065895
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIGH error, NO error, LOW error
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

NCT01299259
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Text Message Reminders
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
15 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional

MPC Versus PID for Closed Loop Insulin Delivery

NCT02438670
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
PID control algorithm, MPC control algorithm
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Jul 22, 2026, 10:05 AM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity

NCT00603603
View directory record Official record
Conditions
Infection; Cesarean Section, Surgical Wound Infection, Endometritis
Interventions
80% inhaled oxygen via non-rebreather mask, 30% inhaled oxygen via nasal cannula
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 50 Years · Female only
Enrollment
606 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 22, 2026, 10:05 AM EDT
Withdrawn Not applicable Interventional

Prevention of Surgical Site Infection After Cesarean Delivery

NCT02027324
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine-alcohol group, Povidone-Iodine Group
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

NCT03277313
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
HYQVIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Hartford, Connecticut • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Results available

Technology Enhanced Community Health Nursing (TECH-N) Study

NCT01640379
View directory record Official record
Conditions
Pelvic Inflammatory Disease (PID)
Interventions
Technology Enhanced Community Health Nursing
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MOCHI: An RCT of Mindfulness as Treatment for Chronic Pelvic Pain in AD Women

NCT04104542
View directory record Official record
Conditions
Chronic Pelvic Pain, Depression, Inflammation Pelvic
Interventions
Mindfulness based stress reduction, Healthy Lifestyle
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 22, 2026, 10:05 AM EDT
Recruiting Phase 1 Interventional

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts

NCT04691622
View directory record Official record
Conditions
Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
Interventions
Norovirus -specific T-cell (NST) therapy
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Months to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Completed No phase listed Observational

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Octagam 5%, Other marketed IVIG product
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
27
States / cities
Granada Hills, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

NCT01313507
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
NewGam
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

NCT03961009
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
North Palm Beach, Florida • Chicago, Illinois • Overland Park, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Terminated Phase 2 Interventional Results available

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
M7824, Placebo, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin, Intensity Modulated Radiation Therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Study of Octanorm Subcutaneous IG in Patients With PID

NCT01888484
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
octanorm 16.5%
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Timing of Prophylactic Antibiotics for Cesarean Sections

NCT00330278
View directory record Official record
Conditions
Endometritis, Wound Infection
Interventions
Cefazolin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Jul 22, 2026, 10:05 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979
View directory record Official record
Conditions
Primary Immunodeficiency Disease
Interventions
Kedrion IVIG 10%
Biological
Lead sponsor
Kedrion S.p.A.
Industry
Eligibility
2 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Centennial, Colorado • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT03840915
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 22, 2026, 10:05 AM EDT
Not yet recruiting Phase 4 Interventional

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions
Cyclobenzaprine
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 10:05 AM EDT
Not listed No phase listed Observational

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

NCT03037359
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Bivigam, Other
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Carpinteria, California • Walnut Creek, California • Centennial, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 22, 2026, 10:05 AM EDT
Completed No phase listed Observational

The Role of Novel Organisms in Acute Endometritis

NCT01236131
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
no intervention
Other
Lead sponsor
Sharon Hillier
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Jul 22, 2026, 10:05 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

NCT01814800
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
RI-002
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Cenntennial, Colorado • North Palm Beach, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Jul 22, 2026, 10:05 AM EDT